Shaman AM, Bain SC, Bakris GL et al (2022) Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER

Key benefits Why people compare it 1 40-60% greater healing outcomes versus either peptide alone 2 Simultaneous activation of early-phase (TB-500) and mid-phase (BPC-157) repair 3 Synergistic upregulation of both VEGF/EGF and actin-migration pathways 4 Dual anti-inflammatory action: NO system modulation plus cytokine reduction 5 Single-vial reconstitution eliminates dosing variability 6 Optimized 1:1 mass ratio matching published combination protocols 7 Thorough tendon, ligament, muscle, and joint repair support 8 No emergent toxicity beyond individual component profiles Deep research About BPC-157 / TB-500 Blend This blend combines two structurally and mechanistically distinct peptides: BPC-157 (a 15-amino acid pentadecapeptide, MW ~1419 Da, sequence GEPPPGKPADDAGLV) and TB-500 (a synthetic 43-amino acid replica of Thymosin Beta-4, MW ~4921 Da)

Tell your healthcare provider if you are taking medicines to treat diabetes including insulin or sulfonylureas which could increase your risk of low blood sugar
Keeps hair, nails and joints strong and healthy
Unfortunately, with food no longer scarce in most developed countries and a plethora of food images served up on social media constantly triggering hunger cues, those age-old instincts are now driving an epidemic of obesity
This appeared to be true even after accounting for the drugs impact on weight loss